TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup

David P. Labbé1,2,15, Christopher J. Sweeney1, Myles Brown1,2, Phillip Galbo3, Spencer Rosario3, Kristine M. Wadosky3, Sheng-Yu Ku1, Martin Sjöström4, Mohammed Alshalalfa5, Nicholas Erho5, Elai Davicioni5, R. Jeffrey Karnes6, Edward M. Schaeffer7, Robert B. Jenkins8, Robert B. Den9, Ashley E. Ross5, Michaela Bowden1, Ying Huang1, Kathryn P. Gray10, Felix Y. Feng11, Daniel E. Spratt12, David W. Goodrich3, Kevin H. Eng13, Leigh Ellis14,§

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA
3Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA
4Department of Clinical Sciences Lund, Oncology and Pathology, Lund University and Skåne University Hospital, Lund, Sweden
5GenomeDx Biosciences, Vancouver, British Columbia, Canada
6Department of Urology, Mayo Clinic, Rochester, MN, USA
7Department of Urology, Northwestern University, IL, USA
8Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
9Department of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
10Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA, 02215
11Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA, USA
12Department of Radiation Oncology, Michigan Center for Translational Pathology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
13Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA
14Department of Oncologic Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, MA, USA
15Present address: Division of Urology, Department of Surgery, McGill University and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada

Background: Current clinical parameters do not stratify indolent from aggressive prostate cancer (PCa). Aggressive PCa, defined by the progression from localized disease to metastasis, is responsible for the majority of PCa-associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of PCa patients, however they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease.

Methods: We have interrogated a total of seven primary PCa cohorts (N = 1,900), two metastatic castration resistant PCa datasets (N = 293) and one prospective cohort (N = 1,385) to assess the impact of TOP2A and EZH2 expression on PCa cellular program and patient outcomes. We also performed immunohistochemical staining for TOP2A and EZH2 in a cohort of primary PCa patients (N = 89) with known outcome. Finally, we explored the therapeutic potential of a combination therapy targeting both TOP2A and EZH2 using novel PCa-derived murine cell lines.

Results: We demonstrate by genome-wide analysis of independent primary and metastatic PCa datasets that concurrent TOP2A and EZH2 mRNA and protein up-regulation selected for a subgroup of primary and metastatic patients with more aggressive disease and notable overlap of genes involved in mitotic regulation. Importantly, TOP2A and EZH2 in PCa cells act as key driving oncogenes, a fact highlighted by sensitivity to combination-targeted therapy.

Conclusions: Overall, our data supports further assessment of TOP2A and EZH2 as biomarkers for early identification of patients with increased metastatic potential that may benefit from adjuvant or neo-adjuvant targeted therapy approaches.
Conflict of Interest: The authors declare no competing financial interests.

Funding Acknowledgments: D.P.L. is supported by a Prostate Cancer Foundation Young Investigator Award, a Cancer Research Society Next Generation of Scientist Scholarship, and a Canadian Institute of Health Research Fellowship. L.E. is supported by a Roswell Park Cancer Institute (RPCI) and a Dana-Farber Cancer Institute faculty start-up funds, and a Prostate Cancer Foundation Young Investigator Award. This study used shared resources supported by the RPCI Cancer Center Support Grant from the NCI (P30CA016056) and was supported by grants from the NIH (R21CA179907 to D.W.G. and R01CA207757 to D.W.G. & L.E.).